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Published data regarding the association between Apolipoprotein E (ApoE) genetic variation and
myocardial infarction (MI) risk were not always consistent. Therefore, the current meta-analysis
was conducted to derive a more precise estimation of the association between ApoE polymorphism
and MI risk. PubMed and Web of Science were searched to identify relevant studies. Summary odds
ratio (ORs) and 95% confidence intervals (CIs) were calculated using random-effect or fixed-effect
models based on the heterogeneity of included studies. All the tests were performed using Stata
11.0. A total of 22 eligible studies were identified in this meta-analysis. The results show that
ApoE e2 and e4 alleles were associated with MI risk. The study suggests that there is close association
between ApoE polymorphism and MI risk. It shows that ApoE e2 allele is a protective factor of MI,
while e4 allele is a risk factor of MI, especially in Caucasian and Asian population. Nevertheless,
well-designed, unbiased and larger sample size studies are required to confirm the results.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Myocardial infarction (MI) is a complex syndrome affected by
multiple predisposing genetic and environmental factors [1]. The
association between ApoE polymorphisms and MI has drawn a
lot of attention. ApoE is a multifunctional protein which plays a
critical role in the metabolism of triglycerides and cholesterol
[2,3], and the corresponding gene is considered as a excellent can-
didate to investigate the etiology of MI [4]. The gene is located at
19q13.2 and possesses three common alleles (e2, e3, e4) and forms
six genotypes (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4 and e4/e4) [5]. As
the previous studies, the ApoE polymorphisms were found to affect
ApoE transcription and the levels of cholesterol and triglyceride
[6,7], which was the main underlying risk factor of MI. However,
the results of the earlier studies were inconsistent. Therefore, a
system review and meta-analysis by collecting and sorting the pre-
viously published studies was conducted.2. Materials and methods
2.1. Identification and eligibility of relevant studies
The online medical databases PubMed andWeb of Science were
used, using the search term ‘‘ApoE/Apolipoprotein E”, ‘‘polymor-
phism/genetic variation” and ‘‘myocardial infarction/MI”. The last
retrieval was conducted in January 2015. The literatures were lim-
ited to papers in English. In addition, studies were identified by
manual search of the references listed in the retrieved studies.
The inclusion criteria were listed as follows: (1) case–control stud-
ies with either a population-based or a hospital-based design; (2)
studies evaluated association between the ApoE polymorphisms
and cancer risk; (3) present sufficient data to calculate an odds
ratio (OR) with 95% confidence interval (CI); (4) not republished
data. Moreover, the studies without raw data or those that were
case-only studies, case reports, editorials and review articles
(including meta-analyses) were eliminated.
2.2. Data extraction
The following detail information were extracted from each
study enrolled in this study by two investigators (YLW and LZ)
independently: the first author’s last name, year of publication,
country of subjects, ethnicity, the source of controls, genotyping
method, matching numbers of genotyped cases and controls and
Y.-L. Wang et al. / FEBS Open Bio 5 (2015) 852–858 853P for Hardy–Weinberg equilibrium (HWE). Furthermore, the dis-
agreements were discussed among all authors and resolved with
consensus.
2.3. Statistical analysis
The association of the ApoE polymorphism and risk of myocar-
dial infarction was estimated by calculating the pooled ORs and
95%CI. The pooled ORs were estimated for seven genetic models
(e2/e2 vs. e3/e3, e2/e3 vs. e3/e3, e2/e4 vs. e3/e3, e3/e4 vs. e3/e3,
e4/e4 vs. e3/e3, e2 allele vs. e3 allele and e4 allele vs. e3 allele).Fig. 1. Flow diagram of the
Table 1
The characteristics of the enrolled studies in this meta-analysis.
First author Year Country Ethnicity Source of control
Tanguturi 2013 India Asian PB
Anand 2009 Mixed Mixed Mixed
Al-Bustan 2009 Kuwaiti Asian HB
Koch 2008 Germany Caucasian PB
Ranjith 2004 Indian African PB
Keavney 2004 UK Caucasian PB
Keavney 2003 UK Caucasian PB
Mamotte 2003 Australia Caucasian PB
Wang 2001 Xinjiang Asian PB
Raslova 2001 Bratislava Caucasian PB
Batalla 2000 Asturias Caucasian PB
Joven 1998 Spanish Caucasian PB
Luc 1994 Belfast Caucasian PB
Luc 1994 Lille Caucasian PB
Luc 1994 Strasbourg Caucasian PB
Luc 1994 Toulouse Caucasian PB
Lenzen 1986 NA Caucasian PB
Kolovou 2002 Greek Caucasian PB
Kumar 2003 North India Asian PB
Baum 2006 Hong Kong Asian HB
Nakai 1998 Japan Asian PB
Hergenc 1995 Turkish Caucasian PB
Utermann 1984 Germany Caucasian PB
NA: not available; PB: population based; HB: hospital based; PCR-RFLP: restriction fragm
study are not enough.Stratified analyses were performed by ethnicity (‘other ethnicity’
group was defined as those ethnicities that contained only one
study). Heterogeneity across the studies was evaluated by using
the Chi-square test based Q-statistic test [8], and it was considered
significant when Pheterogeneity(Ph) < 0.05. The data were combined
using random-effects (the DerSimonian and Laird method) in the
presence of heterogeneity (P < 0.05 or I2 > 50%) and fixed-effects
(the Mantel–Haenszel method) models were used in absence of
heterogeneity (P > 0.05 or I2 < 50%) [9]. Furthermore, the sensitivity
analysis was used to assess the stability of results, and publication
bias was analyzed by Begg’s funnel plot and Egger’s regression teststudy selection process.
Genotyping method Sample size (cases/controls) HWE
PCR-RFLP 202/210 0.097
IlluminaGoldenGate technology 4017/4017 0.091
PCR-RFLP 88/122 <0.050
TaqMan 3657/1211 0.558
PCR-RFLP 195/300 <0.050
PCR-RFLP 4685/3460 –
PCR-RFLP 4484/5757 0.463
PCR-RFLP 359/639 0.732
PCR-RFLP 54/71 0.479
PCR-RFLP 71/71 0.183
PCR-RFLP 220/200 0.776
PCR-RFLP 250/250 0.109
NA 183/176 0.405
NA 64/150 0.932
NA 187/172 0.35
NA 140/182 0.698
NA 570/624 0.081
PCR-RFLP 124/240 0.552
PCR-RFLP 35/45 <0.050
PCR-RFLP 234/336 0.659
PCR-RFLP 254/422 0.175
PCR-RFLP 50/60 0.117
NA 523/1031 <0.050
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854 Y.-L. Wang et al. / FEBS Open Bio 5 (2015) 852–858[10]. Additionally, HWE was used to assess the genotype frequen-
cies of the polymorphism by the chi-square test. All statistical tests
were performed with STATA 11.0 and all the P values were two-
sided.
3. Results
3.1. Characteristics of studies
Based on the search strategy, 571 potentially eligible studies
were identified in the initial search. Among these, 22 studies were
enrolled in this meta-analysis based on the inclusion criteria
[11–32] (Fig. 1). The study by Luc et al. [30] investigated in four
countries and was divided into four studies. The main characteris-
tics of the enrolled 22 studies are summarized in Table 1.
3.2. Quantitative synthesis
In the pooled analysis, significant association was observed
between ApoE polymorphism and risk of myocardial infarction.
The main results were presented in Table 2, and the result of
e2/e3 vs. e3/e3 was also shown in Fig. 2.
Additionally, the subgroup analysis by ethnicity was also con-
ducted, and significant associations with myocardial infarction
were observed in Caucasian (Fig.3) and Asian population. The main
results were presented in Table 2.
3.3. Sensitivity analysis
To assess the stability of the results and assess the source of the
heterogeneity, the sensitivity analysis was performed by omitting
individual eligible study to reflect the influence of the individual
data on the summary ORs. The pooled ORs were not altered for
all comparison models. Among all the enrolled studies, four studies
did not follow HWE, the corresponding summary ORs were not
materially altered with or without these studies. Therefore, the
results of current study were statistically robust. The result of
e2/e2 vs. e3/e3 was shown in Fig. 4.
3.4. Heterogeneity analysis
There was significant between-study heterogeneity in e2/e2 vs.
e3/e3 (P = 0.001, I2 = 63.4), e2/e3 vs. e3/e3 (P = 0.005, I2 = 48.3),
e3/e4 vs. e3/e3 (P = 0.000, I2 = 58.0), e2 allele vs. e3 allele
(P = 0.000, I2 = 64.3) and e4 allele vs. e3 allele (P = 0.000,
I2 = 65.5). In contract, no significant heterogeneity was observed
in other two genetic models (e2/e4 vs. e3/e3: P = 0.750, I2 = 0.0;
e4/e4 vs. e3/e3: P = 0.194, I2 = 20.6). In order to detect the sources
of heterogeneity, the sensitivity analysis was performed based on
HWE and ethnicity. However, the heterogeneity was not materially
altered. As a consequence, we conducted a Galbraith plot to graph-
ically assess the source of heterogeneity. The results indicated that
a total of eight studies contributed to the heterogeneity. Two stud-
ies were the main sources for e2/e2 vs. e3/e3 [20,32] (Fig. 5), three
studies for e2/e3 vs. e3/e3 [15,21,27], four studies for e3/e4 vs. e3/
e3 [16,19,27,32], four studies for e2 allele vs. e3 allele [15,21,27,32]
and five studies for e4 allele vs. e3 allele [11,16,19,27,32], and after
removal of these outlier studies, the heterogeneity was effectively
removed (e2/e2 vs. e3/e3: P = 0.640, I2 = 0.0; e2/e3 vs. e3/e3:
P = 0.828, I2 = 0.0; e3/e4 vs. e3/e3: P = 0.800, I2 = 0.0; e2 allele vs.
e3 allele: P = 0.651, I2 = 0.0; e4 allele vs. e3 allele: P = 0.566,
I2 = 0.0). Meanwhile, the corresponding pooled ORs were not mate-
rially altered in all comparisons. As a consequence, the results of
heterogeneity analysis indicated that our results were statistically
robust and credible.
Y.-L. Wang et al. / FEBS Open Bio 5 (2015) 852–858 8553.5. Publication bias
To evaluate the publication bias of enrolled studies, the Begg’s
funnel plot and Egger’s test were performed. The shapes of funnelFig. 2. Forest plot for ApoE polymorphism and MI
Fig. 3. Forest plot for ApoE polymorphism and MI risk among theplots did not show any obvious asymmetry in all genetic models.
Therefore, the Egger’s test was performed to provide statistical
evidence of funnel plot symmetry, and the results confirmed the
absence of publication bias (Table 3).risk in the genetic model of e2/e3 vs. e3/e3.
Caucasian population in the genetic model of e2/e3 vs. e3/e3.
Fig. 4. The sensitivity analysis in the genetic model of e2/e2 vs. e3/e3. The omitted study is indicated by the first author’s last name.
Fig. 5. Galbraith plot for ApoE gene polymorphism and MI risk in the genetic model of e2/e2 vs. e3/e3.
Table 3
Egger’s test for ApoEpolymorphism.
Egger’s
test
e2/e2 vs.
e3/e3
e2/e3 vs.
e3/e3
e2/e4 vs.
e3/e3
e3/e4 vs.
e3/e3
e4/e4 vs.
e3/e3
t 0.53 0.73 0.6 1.46 0.48
p 0.607 0.474 0.554 0.159 0.638
856 Y.-L. Wang et al. / FEBS Open Bio 5 (2015) 852–8584. Discussion
A total of 22 studies were included in this meta-analysis to
investigate the association between ApoE polymorphisms and MI.
The results of the overall studies showed that the e2/e3 genotype
was associated with a decreased risk of MI, while the e3/e4 and
e4/e4 genotypes were associated with an increased risk of MI.
The current results were in accord with the previous observers,which support the e4 allele as a risk factor of MI [16,33,34]. For
the e2 allele, it was found significantly protective against MI
[12,21]. The discrepancy of the effect on MI risk between different
ApoE genotypes might be supported by earlier studies [35,36]. It
provided evidence that the ApoE E4 coding by e4 allele exhibits
enhanced transfer from HDL to TG-rich lipoproteins, promoting
hepatic remnant clearance by apoE receptors and decreasing LDLR,
thereby increasing cholesterol levels. On the contrary, the ApoE E2
coding by e2 allele binds LDLR poorly, which can increase the LDLR
numbers, thereby lowering cholesterol level. A previous meta-
analysis showed no significant association between e2 carriers
and MI risk (e2 carriers vs. e3/e3: OR = 0.90, 95%CI = 0.76–1.06,
P = 0.120), whereas an increased MI risk with e4 carriers (e4 carri-
ers vs. e3/e3: OR = 1.18, 95%CI = 1.05–1.33, P = 0.003) [37]. By com-
parison, our results were not completely consistent with previous
meta-analysis. The discrepancy may partly result from the genetic
diversity among ethnicities.
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decreased MI risk in e2 carriers, while an increased MI risk in e4
carriers compared with e3 carriers in both Asian and Caucasian
population. These results were consistent with the studies enrolled
in our meta-analysis [11,12,15,19,26,30]. Furthermore, sensitivity
analysis was also performed to make sure whether modification
of the inclusion criteria of the meta-analysis affected the final
results. The results showed that corresponding pooled ORs were
not materially altered in all genetic models which indicated that
the results were statistically robust.
Heterogeneity is a potentially important factor to influence the
interpretation of the current results. In this meta-analysis, signifi-
cant heterogeneity existed in e2/e2 vs. e3/e3, e2/e3 vs. e3/e3, e3/e4
vs. e3/e3, e2 allele vs. e3 allele and e4 allele vs. e3 allele. Common
reasons of heterogeneity may attribute to the diversity in design,
study quality, sample-sizes, genotyping methods, inclusion criteria
and some studies without HWE. To explore the sources of hetero-
geneity, we first performed the sensitivity analyses based on HWE
and ethnicity. However, the heterogeneity was not effectively
removed. Therefore, a Galbraith plot was performed to further
evaluate the source of heterogeneity. After excluding eight outlier
studies, the heterogeneity was effectively removed. Moreover, the
corresponding pooled ORs were not materially altered in all com-
parisons, which also suggested that our results were statistically
robust.
Some limitations of the meta-analysis should be addressed.
Firstly, the potential factors such as gender, age, smoking, drinking,
living habits were not considered in this meta-analysis. Secondly,
between-study heterogeneity should be paid attention, which
may affect the results. Thirdly, only studies in English were
enrolled in this meta-analysis, which may lose some studies in
other languages consistent with inclusion criteria. Regardless of
such limitations, this meta-analysis still had some advantages.
Firstly, all enrolled studies were consistent with inclusion criteria
well. Secondly, no publication bias was observed indicating that
the whole pooled results might be unbiased.
In conclusion, the current meta-analysis of 22 studies indicated
that ApoE e2 allele was a protective factor of MI, while e4 allele was
a dangerous factor of MI, especially in Asian and Caucasian
population. However, the results should be further conformed in
well-designed, unbiased, powered studies.
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